Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial

pemvidutide (ALT-801) - Altimmune

John Suschak1; Shaheen Tomah1; Julio Gutierrez1; M. Scot Roberts1; Rachel Garner1; Sarah Browne1; M. Scott Harris1; Christophe Arbet-Engels1

Mar 18, 2026